Please assess the completion status of the following clinical trial:

Trial Title: S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of lymphoma of 1 of the following types:~  * Diffuse large B-cell lymphoma~ * Follicular lymphoma~    * Grades 1, 2, or 3~ * Primary mediastinal lymphoma~ * Mantle cell lymphoma~ * Small lymphocytic lymphoma~ * Hodgkin's lymphoma~ * Transformed lymphoma~* Relapsed after prior autologous bone marrow transplantation (BMT)~  * More than 180 days post BMT~* Received ≥ 1 course of chemotherapy after BMT relapse~  * Achieved a complete response OR a partial response to chemotherapy~    * Largest residual tumor dimension ≤ 2 cm~* No clinical or laboratory evidence of CNS involvement by lymphoma~* HLA-identical donor available, meeting 1 of the following criteria:~  * Sibling donor with 5/6 or 6/6 alleles matching by genotyping~    * No monozygotic identical twins~ * Unrelated donor with 10/10 alleles matching by genotyping~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Cardiovascular~* LVEF ≥ 40% by MUGA or 2-D echocardiogram (2-D ECHO)~* No significant cardiac abnormalities by MUGA or 2-D ECHO~* No uncompensated coronary artery disease by ECG or physical exam~* None of the following within the past 6 months:~  * Myocardial infarction~ * Unstable angina~ * Uncontrolled atrial fibrillation~* None of the following within the past 3 months:~  * Severe peripheral vascular disease~ * Venous stasis ulcers~ * Deep venous or arterial thrombosis~* No uncontrolled hypertension~Pulmonary~* DLCO (corrected) and total lung capacity ≥ 40% of predicted~* No requirement for continuous supplemental oxygen~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* No AIDS~* No active bacterial, viral, or fungal infection~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No history of uncontrolled seizures~* No diabetic ulcers within the past 3 months~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~* No more than 1 prior bone marrow transplantation~Chemotherapy~* See Disease Characteristics~* More than 21 days since prior chemotherapy and recovered~Endocrine therapy~* Not specified~Radiotherapy~* More than 4 weeks since prior radiotherapy~Surgery~* More than 4 weeks since prior major surgery except placement of a venous access device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nonmyeloablative allogeneic stem cell transplant (Type: EXPERIMENTAL): Patients are given fludarabine 30 mg/m\^2 on days -6 to -2 and melphalan 70 mg/m\^2 on days -3 and -2, then transplanted with donor peripheral blood stem cells or harvested bone marrow stem cells on day 0. Patients are then given post-transplant immunosuppression consisting of tacrolimus 0.06 mg/kg/day on days -3 to 100 and methotrexate 5 mg/m\^2 on days 1, 3, and 7.

Based on this trial design, predict the completion outcome and termination type (if applicable).